Actively Recruiting
Impact of Erector Spinae Plane Block on Chronic Postsurgical Pain in Breast Cancer Patients
Led by Peking University First Hospital · Updated on 2025-07-31
1206
Participants Needed
2
Research Sites
214 weeks
Total Duration
On this page
Sponsors
P
Peking University First Hospital
Lead Sponsor
P
Peking University Cancer Hospital & Institute
Collaborating Sponsor
AI-Summary
What this Trial Is About
Chronic postsurgical pain (CPSP) has an incidence of 46% in patients after breast cancer surgery, which seriously affects patients' physiological and psychological function, as well as quality of life. Acute pain is an independent risk factor for persistent pain after surgery. Erector spinae plane block (ESPB) provided excellent perioperative analgesia in patients undergoing breast surgery. Dexmedetomidine as an adjuvant of local anesthetics prolongs the duration of peripheral nerve block and decreases the requirements of postoperative analgesia. The investigators hypothesize that, for breast cancer patients undergoing mastectomy, ESPB (with a combination of 0.5% ropivacaine 35 ml and dexmedetomidine 1 microgram/kg) can reduce the occurrence of CPSP. The purpose of this randomized controlled trial is to investigate the impact of ESPB with adjuvant dexmedetomidine on the incidence of CPSP in breast cancer patients after mastectomy. We will also observe the impact of ESPB on long-term survival in these patients.
CONDITIONS
Official Title
Impact of Erector Spinae Plane Block on Chronic Postsurgical Pain in Breast Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age of 18 years or over, but less than 85 years
- Scheduled to undergo mastectomy for primary unilateral breast cancer
You will not qualify if you...
- Previous breast cancer surgery with an incision larger than 2 cm
- Chronic opioid dependence or long-term use of analgesic medicines for more than 3 months
- Contraindications to erector spinae plane block, including intrathoracic infection, infection at the puncture site, cancer invasion at the puncture site, severe spinal deformity, history of spinal surgery, and severe coagulopathy
- Inability to communicate before surgery due to profound dementia, deafness, language barriers, or end-stage disease
- History of malignant tumors in other organs or concurrent malignant tumors in other organs
- History of coronary heart disease, preoperative liver or kidney impairment, history of peptic ulcer or hemorrhage, or ASA classification IV or above
- Allergy to ropivacaine
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Peking University First Hospital
Beijing, Beijing Municipality, China, 100034
Actively Recruiting
2
Beijing Cancer Hospital
Beijing, Beijing Municipality, China, 100142
Actively Recruiting
Research Team
Q
Qiongfang Wu, M.D.
CONTACT
D
Dong-Xin Wang, M.D., Ph.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here